Ellen K. Donnelly

Ellen K. Donnelly, born 1974, is a highly experienced and strategic drug development executive. She has held leading positions in both large and small pharma/biotech companies, including as CEO of Modus Therapeutics AB (Sweden), CEO of Souvien Therapeutics (US), CEO of the Epigenetics Division of Juvenescence (UK) and she has spent almost a decade at Pfizer, Inc. (US) in a variety of leadership positions. Ellen’s expertise includes business and clinical development strategies, as well as interacting with specialized investors, especially in the US. She also has experience in management consulting. Ellen has a Ph.D. in Pharmacology from Yale University.